Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ORIC Pharmaceuticals, Inc. ORIC
$5.14
-$0.03 (-0.68%)
На 18:02, 12 мая 2023
+36.19%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
231994224.00000000
-
week52high
6.85
-
week52low
2.36
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.48000000
-
EPS
-2.25000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Citigroup | Buy | Buy | 20 мая 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 25 мар 2022 г. |
| Oppenheimer | Perform | Outperform | 22 мар 2022 г. |
| Guggenheim | Neutral | Buy | 22 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 10 ноя 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Chacko Jacob | A | 66000 | 66000 | 01 февр 2023 г. |
| Chacko Jacob | A | 400000 | 400000 | 01 февр 2023 г. |
| Piscitelli Dominic | A | 24000 | 24000 | 01 февр 2023 г. |
| Piscitelli Dominic | A | 145000 | 145000 | 01 февр 2023 г. |
| Multani Pratik S | A | 24000 | 24000 | 01 февр 2023 г. |
| Multani Pratik S | A | 145000 | 145000 | 01 февр 2023 г. |
| Multani Pratik S | D | 12084 | 6041 | 15 дек 2022 г. |
| Multani Pratik S | D | 7423 | 2089 | 15 дек 2022 г. |
| Multani Pratik S | A | 9512 | 6041 | 15 дек 2022 г. |
| Chacko Jacob | D | 33334 | 16666 | 15 дек 2022 г. |
Новостная лента
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewsWire
01 февр 2023 г. в 16:30
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February:
ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 16:30
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 11:15 a.m. PT.
New Years Penny Stocks Trading Advice: 3 Tips
PennyStocks
23 дек 2022 г. в 06:00
What you need to know about trading penny stocks as the year ends The post New Years Penny Stocks Trading Advice: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study
Zacks Investment Research
22 дек 2022 г. в 12:48
ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter's elranatamab in multiple myeloma. Stock up in after-hours trading.
Oric's stock rallies on multiple myeloma deal with Pfizer
Market Watch
22 дек 2022 г. в 08:38
Shares of Oric Pharmaceuticals Inc. ORIC, +2.04% soared about 56% in premarket trading on Thursday, the day after the company said it will collaborate with Pfizer Inc. PFE, +0.66% to develop a multiple myeloma therapeutic candidate. Pfizer will pay $4.65 per share for 5,376,344 of Oric's common shares, for a total of $25 million.